Minocycline and Rifampin: The AIGISRx™ Antibiotics

AIGISRx™ elutes the powerful antibiotic combination of rifampin and minocycline, both of which have been extensively tested in various indwelling devices. In in vitro studies, AIGISRx™ CRMD has demonstrated antimicrobial activity against Methicillin Resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter baumanii, Enterobacter aerogenes, and Proteus mirabilis, which represent a majority of the infections reported in CRMD-related endocarditis, including “superbugs” or MRSA.

There is a strong clinical rationale behind the combination of rifampin and minocycline selected for the AIGISRx™. Rifampin and minocycline provide a broad spectrum of activity against the most common colonizing bacteria and against bacteria in tissues and fluids. Extensive in vitro testing with central venous catheters has demonstrated that this combination of antibiotics is safe and effective:

  • Superior to a combination of chlorhexidine and silver sulfadiazine1
  • Superior to vancomycin, clindamycin, novobiocin and minocycline alone2
  • Equivalent to ceftazidime or amphotericin B against gram negative bacilli and Candida albicans

  1. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340(1):1-8.
  2. Raad II, Darouiche RO, et al. Antibiotics and prevention of microbial colonization of catheters. Antimicrobial Agents Chemother. 1995:2397-2400.